Date: 2015-12-01
Type of information: Collaboration agreement
Compound: EAPB02303
Company: Institut des Biomolécules Max Mousseron - IBMM (France) SATT AxLR (France) 4P Pharma (France)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On December 1, 2015, IBMM, SATT AxLR and 4P Pharma announced they have concluded a co-development maturation agreement for an amount of € 436,400, with a licensing option. The financing for this programme, called “Imiqualines” is shared between SATT AxLR and 4P Pharma.
IBMM’s research activities are located at the interface between chemistry and biology while trying to understand the actions of biomolecules and pathologies, with the goal of proposing tomorrow’s medical drugs. Research undertaken by IBMM has made it possible to identify a new molecule - EAPB02303 - capable of destroying tumour cells very effectively, notably in melanoma and pancreatic cancer models. The work to be carried out within the framework of the co-development programme between
SATT AxLR and 4P Pharma falls within the scope of oncological and-pharmaco-chemical development that requires bringing the reduction of metastatic occurrences to the forefront. Molecules, currently in development, however, do not meet all the challenges of cancer progression and resistance mechanisms emerge. From now on, therapeutic treatments must address cancer molecular characteristics, beyond the organ of origin. In this context, a given targeted therapy may be used to address very different types of cancer by targeting a common molecular characteristic. The “Imiqualines” development project is being developed in this context and under this reasoning.
“Imiqualines” project’s maturation phases will be implemented by 4P Pharma and will enable to characterise the original mechanism of action of EAPB02303, to prove its efficacy for several cancer indications and to assess its toxicity. Should this maturation programme yield positive results, it is envisaged that 4P Pharma will exercise the licensing option in the last quarter of 2016 and continue regulatory preclinical development until the first clinical phase in patients.
Financial terms: t
Latest news:
